Abstract
Background
The clinical management of children with renal tumors including Wilms’ tumor, clear cell sarcoma, rhabdoid tumor and other renal tumors in our center was designed according to the National Wilms’ Tumor Study Group protocols.
Methods
A total of 142 consecutive patients who had been diagnosed as having renal tumors at Shanghai Children’s Medical Center were reviewed retrospectively in the period of December 1998 and September 2012. Diagnosis and treatment were decided by a multidisciplinary team including oncologists, surgeons, pathologists and sub-specialized radiologists.
Results
The median age of the patients at the time of diagnosis was 27 months. The tumor stages of the patients were as follows: stage I 24.6%, stage II 23.2%, stage III 32.3%, stage IV 14.1%, and stage V 5.6%. Favorable histology was diagnosed in 80.3%, anaplasia in 4.2%, clear cell sarcoma in 9.8%, rhabdoid tumor in 4.9%, and other renal tumors in 0.7% of the patients. The eventfree and overall 5-year survival rates were 80% and 83%, respectively. Tumor relapse and progress was seen in 25 patients (17.6%). The median relapse time was 6 months (range: 2-37 months). Seven relapsing patients were retreated and four of them got second complete remission (three in stage II, one in stage I).
Conclusion
A multi-disciplinary team work model is feasible in developing countries, and the renal tumors protocols basically from developed countries are safe in developing countries.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dome JS, Perlman EJ, Ritchey ML, Coppes MJ, Kalapurakal J, Grundy PE. Renal tumors. In: Poplack DG, Pizzo PA, eds. Principles and Practice of Pediatric Oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006: 905–932.
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625–2634.
Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, et al. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol 2012;27:1325–1333.
Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, et al. Management of Wilms’ tumour: current practice and future goals. Lancet Oncol 2004;5:37–46.
Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1998;16:3744–3751.
D’Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, et al. The treatment of wilms’ tumor: results of the third National Wilms’ Tumor Study Group. Cancer 1989;64:349–356.
Hamilton TE, Ritchey ML, Haase GM, Argani P, Peterson SM, Anderson JR, et al. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Ann Surg 2011;253:1004–1010.
Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005;174:1972–1975.
Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, et al. Treatment of anaplastic histology Wilms’ tumor: results from the fi fth National Wilms’ Tumor Study. J Clin Oncol 2006;24:2352–2358.
Popov SD, Sebire NJ, Pritchard-Jones K, Vujanic GM. Renal tumors in children aged 10–16 years: a report from the United Kingdom Children’s Cancer and Leukaemia Group. Pediatr Dev Pathol 2011;14:189–193.
Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010;251:555–558.
Metzger ML, Dome JS. Current therapy for Wilms’ tumor. Oncologist 2005;10:815–826.
Pritchard J, Imeson J, Barnes J, Cotterill S, Gough D, Marsden HB, et al. Results of the United Kingdom Children’s Cancer Study Group first Wilms’ Tumor Study. J Clin Oncol 1995;13:124–133.
Venkatramani R, Malogolowkin M, Davidson TB, May W, Sposto R, Mascarenhas L. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One 2013;7:e68416.
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008;50:236–241.
Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 2002;13:460–469.
Metzger ML, Stewart CF, Freeman BB 3rd, Billups CA, Hoffer FA, Wu J, et al. Topotecan is active against Wilms’ tumor: results of a multi-institutional phase II study. J Clin Oncol 2007;25:3130–3136.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pan, C., Cai, JY., Xu, M. et al. Renal tumor in developing countries: 142 cases from a single institution at Shanghai, China. World J Pediatr 11, 326–330 (2015). https://doi.org/10.1007/s12519-015-0041-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-015-0041-3